Enmetazobactam API is a synthetic β-lactamase inhibitor belonging to the penicillanic acid sulfone class. It is designed to inhibit extended-spectrum β-lactamases (ESBLs), thereby protecting susceptible β-lactam antibiotics from enzymatic degradation.
Enmetazobactam is used in combination with cefepime. The combination is marketed as Exblifep and provides an antibacterial treatment option for infections caused by susceptible Gram-negative bacteria producing certain β-lactamases.
Enmetazobactam, formerly known as AAI-101, is a β-lactamase inhibitor that has activity against a broad range of class A ESBLs, including CTX-M, TEM and SHV enzymes. By inhibiting these enzymes, Enmetazobactam helps protect cefepime from hydrolysis and restores its antibacterial activity against susceptible organisms.
Enmetazobactam has the molecular formula C₁₁H₁₄N₄O₅S, molecular weight 314.32 g/mol, and CAS number 1001404-83-6.
Swapnroop Drugs and Pharmaceuticals provides Enmetazobactam API for qualified pharmaceutical manufacturing, formulation development, research and pharmaceutical sourcing requirements.
Enmetazobactam is a specialized antibacterial pharmaceutical ingredient relevant to β-lactam/β-lactamase inhibitor combination products.
Enmetazobactam inhibits β-lactamase enzymes produced by resistant Gram-negative bacteria. These enzymes can hydrolyze β-lactam antibiotics and reduce their antibacterial activity. By inhibiting susceptible β-lactamases, Enmetazobactam protects cefepime from enzymatic degradation.
Enmetazobactam is associated with:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.5 – 6.5 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |